Thymosin Beta-4
Thymosin Beta-4
Regulatory Status
Part of the ongoing FDA review of compounded peptides.
FDA · Updated Apr 2026
Generally treated as research-only.
MHRA · Updated Apr 2026
Restricted or prescription-only depending on channel.
TGA · Updated Apr 2026
Restricted in sport due to performance and healing concerns.
WADA · Updated Apr 2026
Overview
Thymosin Beta-4 is the parent peptide associated with the shorter fragment often sold as TB-500. It is mostly discussed for wound-healing and tissue-repair applications, but it remains in the higher-risk bucket of the FDA conversation.
Research Snapshot
- Mechanistic interest centers on actin regulation and tissue repair
- Human evidence remains limited relative to the enthusiasm around the peptide
- Often confused with TB-500 in commercial marketing
Continue Reading
Readers also explore
State of Peptides 2026
Get the free report and peptide profile updates.
Evidence notes, regulatory changes, and practical research guides in your inbox. Education only - not medical advice.
Get the PeptideUnicorn update
New profiles, regulatory changes, practical guides, and vendor review notes delivered to your inbox.
Get our free State of Peptides 2026 report when you subscribe.